Lipinski is a Adjunct Senior Research Fellow, Groton Laboratories,
Pfizer Global Research and Development, Groton, Connecticut.
He obtained a Ph.D. from the University of California, Berkeley,
and did his postdoctoral training at Caltech, supported
by the National Institute of General Medical Sciences. After
joining Pfizer in 1970, he supervised medicinal chemistry
laboratories, discovering multiple gastrointestinal and
diabetic clinical candidates. In 1990, he established a
laboratory combining computations and experimental physical-property
measurements. He is the author of "The Rule of Five," a
widely used filter for drug-like properties. Dr. Lipinski
serves on the highlights panel of Nature Reviews Drug Discovery,
the Conference Advisory Board of Cambridge HealthTech, as
a consultant to the Hereditary Disease Foundation and serves
on the Editorial Advisory Board of Current Drug Discovery
Techniques. Since 1984, he has been an adjunct faculty member
at Connecticut College in New London, Connecticut, and has
over 160 publications and invited presentations and 17 issued
J. WARD, Ph.D
Executive Advisor to Biotech,
their Investors and Suppliers
Dr. Ward has
over 20 years operational experience in major Pharma and
as a corporate office in successful Biotech, with responsibilities
in drug discovery and development, supporting technology
and process development, and corporate strategy.
a research scientist in central nervous system disorders,
Susan began her research career at Sterling Drug in 1982.
In 1993, she joined Wyeth Research as Vice President of
Research (UK) and Vice President of CNS Disorders
worldwide. Adopting responsibility for Project Management
and the Wyeth Drug Development Portfolio in 1996, Susan
oversaw the development of 30+ new and life cycle extension
products, including global approvals for Enbrel, Mylotarg,
Sonata, Rapamune and Protonix, and label extensions for
Efexor and Women’s Health products. She established
one of the first project management capabilities in drug
discovery in the industry, halving time to first studies
in man, and improving productivity in several steps in the
corporate senior team of Millennium Pharmaceuticals Inc.
in 2000, Susan led the evolution of Millennium’s successful
genome technology platform into downstream R&D areas,
established knowledge management capability, and integrated
these into a comprehensive Productivity strategy and platform.
Susan worked with Infinity Pharmaceuticals, first as an
advisor to its inception and early start-up, and than as
Executive Vice President establishing a cutting-edge and
integrated platform operational and strategic platform designed
to aid productivity of both scientists and business functions.
Dr. Ward is
now an Executive Advisor to Biotechnology, sometimes joining
the senior management team of a company at a strategic transition
point for an interim period of time. She is the founding
CSO of Syngenetic, a software company dynamically integrating
disparate information sources for the Life Sciences, and
serves on the Advisory Boards of Timeblaster, Ingenuity,
and Business Engine software companies. Susan established
the initial research strategy and plan for Alnylam Pharmaceuticals,
a leading RNA-interference company, and undertakes shorter
consults in Biotech, recent clients including Viropharma,
Adolor, Abgenix, and several venture capital firms.
HERSCHEL J. R. WEINTRAUB, Ph.D
Principal Consultant, IBM Life
Sciences, Peoria, Arizona
Weintraub received his Ph.D. in Macromolecular Science from
Case Western Reserve University in 1975. He also holds
a B.S. in Biomedical Engineering from Case Institute of
Technology. Following postdoctoral research in Medicinal
Chemistry at the Purdue University School of Pharmacy, he
served on the faculty of the Department of Medicinal Chemistry
and Pharmacognosy at Purdue as an Assistant Professor of
Medicinal Chemistry. In 1978, he was awarded a USPHS
National Library of Medicine Fellowship in Computer Science
at the University of Illinois. Dr. Weintraub maintained
his appointment at Purdue until 1982, when he joined the
Lilly Research Laboratories as Senior Physical Chemist.
He subsequently joined the Computer-Assisted Molecular Design
group at Abbott Laboratories, and in 1986 established the
Theoretical Chemistry Department at Merrell Dow Pharmaceuticals
(now Aventis). During the period from 1986 until 1993,
as Head of Global Theoretical Chemistry and Scientific Supercomputing,
Herschel was instrumental in the acquisition of graphics
systems, major modeling software, and a Cray Supercomputer
for Molecular Design and Structural Chemistry applications.
In 1993, Dr. Weintraub moved to the R.W. Johnson Pharmaceutical
Research Institute as Assistant Director of Discovery Research,
Computer-Assisted Drug Discovery. In 1997, Herschel
accepted the position of Vice President, Computational Chemistry
and Informatics, at Helios Pharmaceuticals in Louisville,
Kentucky. He then served as Director of Scientific
Computing at Genentech, Inc. in South San Francisco, California
until 2001. After working as an independent consultant
in the area of Pharmaceutical and Biotech R&D Informatics
and Molecular Modeling, Herschel joined IBM Life Sciences
as a Principal Consultant.
is the author of CAMSEQâ, developed in 1973 as the first
commercial molecular modeling application for “small molecule”
drug design, and CAMSEQ/M, a PC-based graphical molecular
modeling program, developed in 1979.
is the author of over 30 scientific publications, including
6 book chapters on subjects related to molecular modeling
and drug design. His research interests lie in the
areas of Pharmaceutical Informatics, Computer-Assisted Drug
Discovery, Structural Chemistry, Combinatorial Chemistry
and Diversity, and applications development in these fields.
He is past chair of the Gordon Conference on QSAR.
He is also
an associate faculty member in the Molecular Design Institute
of the University of California at San Francisco and serves
on the Advisory Board of Current Drug Discovery.
President, New Medicine Partners
has had more than 20 years of experience in the health care
industry and has held a range of senior leadership roles,
in both early stage and mature companies, and in consulting.
He leads New Medicine Partners, a firm focused on assisting
growth stage biotechnology and pharmaceutical companies
to address issues of strategy, product development &
commercialization, M&A and knowledge management.
He also is a co-founder and Board member of Homeland Defense
Ventures, which - among other activities - assists investors
and companies seeking to enter the rapidly growing biodefense
market. He is also a member of the board of Exact
Sciences, an applied genomics company commercializing cancer
Prior to founding
NMP, he was President and CEO of iKnowMed, an Internet-based
clinical decision support service that provides leading
oncologists with real-time information on treatment regimens
and clinical trials, and collects critical point-of-care
data on drug usage for pharmaceutical companies.
Prior to iKnowMed,
Dr. Barker was CEO of Chiron Diagnostics, a $600 million
division of the biotechnology company Chiron, developing
and marketing diagnostic systems worldwide. He restructured
the company’s business for improved profitability, directed
the launch of several major new products, and led merger-and-acquisition
discussions with prospective partners prior to Bayer's acquisition
of the company. He also played a leading role at Chiron
in strategy and business development.
he was the first General Manager of International Business
Machines' $2 billion worldwide health care solutions business;
he led this unit in the creation of information solutions
and was responsible for marketing and sales to major clients
operating positions, Dr. Barker spent 13 years with McKinsey
& Company, leading that firm's pharmaceuticals practice
has a D.Phil. in biophysics and a BA in Chemistry, both
SHOIBAL DATTA, Ph.D
Director, Life Science Practice, Tibiosys,
heads the Life Sciences Practice at Tribiosys. He has over
12 years of research experience in the Life Sciences. Dr.
Datta has conducted research in the areas of molecular retrovirology,
cancer biology, chromatin structure and function, gene expression
and gene therapy. At Tribiosys, he is responsible for defining
the Life Sciences services for the company and has participated
in multiple knowledge management projects for leading biopharmaceutical
organizations. Prior to joining Tribiosys he was a Lecturer
at the University of California, Irvine, where he taught
courses on AIDS, Molecular Biology of Cancer and Computational
Shiv Tasker, a partner with Emsan Consulting, heads the
start up and emerging growth company practice with focus
on business and marketing strategy. Prior to Emsan
Consulting, Shiv was the president and CEO of Phase Forward,
a software and service solution vendor for the data collection
and management of clinical trials of new drugs and devices.
Prior to Phase
Forward, Shiv was Sr. Vice President for Worldwide Sales,
Consulting Services and Corporate Marketing at Viewlogic
Systems Inc, a supplier of complex electronic design automation
tools for Integrated Circuit and Printed Circuit Board design.
As SVP of Sales, Viewlogic had successive quarters of record
growth ($200M run rate) till the company’s sale to a larger
competitor. He improved service gross margins from
27% to 62% within 6 quarters and successfully branded the
company away from its historical slower growing products
to a new set of hot growth products that led to the company
being viewed as a serious acquisition target.
spent 8 years at Cadence Design Systems in a variety of
roles in marketing and general management with ever increasing
responsibility for product lines and larger P&Ls.
Prior to Cadence, he was with Intergraph Corp for 5.5 years,
initially as a programmer and later as a marketer.
holds an MBA from the University of Texas at Arlington and
a BS from the University of Bombay in Statistics and Economics.
He is a member of the Drug Information Association and works
with the Youth Technology Entrepreneurs, a non-profit organization
aimed at enriching high school curriculums with real life
technology skills - primarily in lower income school districts.
He was recently honored by Mass Hi-Tech as an All-Star